JOHNSON & JOHNSON (JNJ)
A+
Pipeline Grade
Financial Position (from SEC Filings)
$21,688.0M
Cash & Equivalents
$2,514.0M
Quarterly Burn Rate
$618,607M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (44 Assets)
| Drug | Phase | Indications |
|---|---|---|
|
PENTOSAN POLYSULFATE SODIUM
ELMIRON |
APPROVED | — |
|
APALUTAMIDE
ERLEADA |
APPROVED | — |
|
USTEKINUMAB
STELARA |
APPROVED | — |
|
ESKETAMINE HYDROCHLORIDE
SPRAVATO |
APPROVED | — |
|
ABIRATERONE ACETATE, NIRAPARIB TOSYLATE
AKEEGA |
APPROVED | — |
|
GUSELKUMAB
TREMFYA |
APPROVED | — |
|
AMIVANTAMAB AND HYALURONIDASE-LPUJ
RYBREVANT FASPRO |
APPROVED | — |
|
ERDAFITINIB
BALVERSA |
APPROVED | — |
|
DARATUMUMAB AND HYALURONIDASE-FIHJ
DARZALEX FASPRO |
APPROVED | — |
|
GOLIMUMAB
SIMPONI ARIA |
APPROVED | — |
|
CANAGLIFLOZIN
INVOKANA |
APPROVED | — |
|
PALIPERIDONE PALMITATE
INVEGA TRINZA |
APPROVED | — |
|
ICOTROKINRA HYDROCHLORIDE
ICOTYDE |
APPROVED | — |
|
AMIVANTAMAB-VMJW
RYBREVANT |
APPROVED | — |
|
TECLISTAMAB-CQYV
TECVAYLI |
APPROVED | — |
|
TALQUETAMAB-TGVS
TALVEY |
APPROVED | — |
|
CANAGLIFLOZIN, METFORMIN HYDROCHLORIDE
INVOKAMET |
APPROVED | — |
|
LAZERTINIB MESYLATE
LAZCLUZE |
APPROVED | — |
|
DARATUMUMAB
DARZALEX |
APPROVED | — |
|
NIPOCALIMAB-AAHU
IMAAVY |
APPROVED | — |
|
TRAMADOL HYDROCHLORIDE
ULTRAM |
APPROVED | — |
|
PALIPERIDONE
INVEGA |
APPROVED | Acetaminophen, Acetaminophen Exposure, Acetaminophen Overdose, Acetaminophen Poisoning, Achalasia, Acinetobacter Bacteremia, Acinetobacter Pneumonia, Acne, Acne Vulgaris, Acute Coronary Syndrome, Acute Myeloid Leukemia, Acute Pain, Acute Respiratory Infection, Adnexal Diseases, Adolescent Health Services, Adult Skin Healthy Signs, Adult Smokers, Advance Care Planning, Advanced Malignancies, Advanced Prostate Cancer, Affective Disorders, Psychotic, Aggressive B-cell NHL, Aging, Alcohol Abuse, Alcohol Dependence, Alcoholic Intoxication, Alcoholism, Allergic Rhinitis, Allergic Sensitization, Allergy, Allergy and Asthma, Alopecia, Alveolar Bone Loss, Alzheimer Disease, Alzheimer's Disease, Ambulatory Care, Ametropia, Amyloidosis, Analgesics, Androgenetic Alopecia, Anemia, Ankle Arthritis, Antineoplastic Protocols, Aortic Aneurysm, Apathy, Appendicitis, Arrhythmias, Cardiac, Arthralgia, Arthritis, Psoriatic, Asthenopia, Asthma, Astigmatism, Atopic Dermatitis, Atrial Fibrillation, Atrial Flutter, Attention Deficit |
|
ETHINYL ESTRADIOL, NORELGESTROMIN
ORTHO EVRA |
APPROVED | — |
|
HALOPERIDOL
HALDOL |
NDA | — |
|
GRISEOFULVIN, MICROCRYSTALLINE
GRIFULVIN V |
NDA | — |
|
MECLOCYCLINE SULFOSALICYLATE
MECLAN |
NDA | — |
|
BEPRIDIL HYDROCHLORIDE
VASCOR |
NDA | — |
|
ALMOTRIPTAN MALATE
AXERT |
NDA | — |
|
TOPIRAMATE
TOPAMAX |
NDA | — |
|
KETOCONAZOLE
NIZORAL |
NDA | Ametropia, Amyloidosis, Anastomotic Leak, Androgenetic Alopecia, Anemia, Apathy, Appendicitis, Athlete's Foot, Atopic Dermatitis (AD), Bariatric Surgery Candidate, Bipolar Disorder, Brain Vascular Accident, CAM, Cancer, Caregiver, Carotid Artery Disease, Carotid Stenosis, Cataract, Cataracts, Chronic Conditions Faced by Medicaid Recipients With Disabilities, Cocaine-Related Disorders, Colorectal Cancer, Colorectal Cancer Screening, Common Childhood Illnesses, Consumer Behavior, Consumer Preference, Corneal Infiltrative Events, Corneal Inflammation, Corneal Swelling, Coronavirus Infection, Dermatitis Atopic, Diabetes, Drug Interaction, Femoro Acetabular Impingement, Fibromyalgia, Food Labeling, Foot Fungus, Gastroenteritis Acute, Health, Healthy, Healthy Term Infants Solely Formula Fed, Heart Disease, Hematologic Malignancy, Hemostasis, Surgical, Histamine Induced Itch, HIV, Infant Development, Lapsed Contact Lens Wear, Leukemia, Lymphocytic, Chronic, B-Cell, Life-limiting Serious Illness, Liposarcoma,Myxoid, |
|
GEMCITABINE HYDROCHLORIDE
INLEXZO |
NDA | — |
|
ITRACONAZOLE
SPORANOX |
NDA | — |
|
ETHINYL ESTRADIOL, NORETHINDRONE
ORTHO-NOVUM 7/7/7-21 |
NDA | — |
|
GALANTAMINE HYDROBROMIDE
RAZADYNE ER |
NDA | — |
|
TERCONAZOLE
TERAZOL 3 |
NDA | — |
|
FENTANYL
DURAGESIC-50 |
NDA | — |
|
NORETHINDRONE
MICRONOR |
NDA | — |
|
CLADRIBINE
LEUSTATIN |
NDA | — |
|
MEBENDAZOLE
VERMOX |
NDA | — |
|
DESOGESTREL, ETHINYL ESTRADIOL
ORTHO-CEPT |
NDA | — |
|
ACETAMINOPHEN, TRAMADOL HYDROCHLORIDE
ULTRACET |
NDA | — |
|
CISAPRIDE MONOHYDRATE
PROPULSID |
NDA | — |
|
ETHINYL ESTRADIOL, NORGESTIMATE
ORTHO TRI-CYCLEN LO |
NDA | — |
|
HALOPERIDOL DECANOATE
HALDOL |
NDA | — |
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2026-07-24 | Phase3 Readout | — |
| 2026-08-04 | Phase2 Readout | — |
| 2026-08-31 | Phase2 Readout | — |
| 2026-11-19 | Phase2 Readout | — |
| 2026-12-01 | Phase1 Readout | — |
| 2026-12-01 | Phase3 Readout | — |
| 2026-12-04 | Phase1 Readout | — |
| 2026-12-08 | Phase1 Readout | — |
| 2026-12-30 | Phase3 Readout | — |
| 2026-12-31 | Phase1 Readout | — |
| 2026-12-31 | Phase1 Readout | — |
| 2026-12-31 | Phase3 Readout | — |
| 2026-12-31 | Phase1 Readout | — |
| 2027-01-01 | Phase2 Readout | — |
| 2027-01-01 | Phase2 Readout | — |
| 2027-01-07 | Phase1 Readout | — |
| 2027-02-10 | Phase1 Readout | — |
| 2027-02-10 | Phase3 Readout | — |
| 2027-02-11 | Phase2 Readout | — |
| 2027-02-26 | Phase2 Readout | — |
Active Clinical Trials (50)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT03229200 | Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib. | PHASE4 | Active Not Recruiting | 297 |
| NCT05525585 | Early Human Milk Fortification After Early, Exclusive, Enteral Nutrition in Very Preterm Infants | OTHER | Active Not Recruiting | 80 |
| NCT04574518 | Teachable Moment to Opt-out of Tobacco: Interactive Voice Response Quit Line for Veteran Active Smokers With Lung Nodule... | OTHER | Active Not Recruiting | 223 |
| NCT05903885 | A Cross-sectional Partnership to Improve Prevention and Health Equity Among African Americans | OTHER | Recruiting | 1,200 |
| NCT02390973 | Surgery Versus Best Medical Management for the Long Term Remission of Type 2 Diabetes and Related Diseases (REMISSION) | OTHER | Recruiting | 408 |
| NCT06763432 | Positive Fit to Colonoscopy: Closing the Gap | OTHER | Recruiting | 45 |
| NCT07220824 | A Study of Guselkumab in Participants With Psoriatic Arthritis (PsA) in a Real-World Setting | OTHER | Recruiting | 200 |
| NCT07228312 | A Study of Choydar Flow-Directed Mesh Stent in the Treatment of Unruptured Intracranial Aneurysms | OTHER | Recruiting | 200 |
| NCT07361055 | The Best Workflow for Paroxysmal Supraventricular Tachycardia Ablation With Zero-fluoroscopy | OTHER | Enrolling By Invitation | 70 |
| NCT07655479 | Rapid Microaxial Flow Pump Support and Escalation in Patients With Myocardial Infarction Associated Cardiogenic Shock an... | OTHER | Recruiting | 115 |
| NCT05734638 | Stress and Blood Pressure Management for Caregivers | OTHER | Active Not Recruiting | 90 |
| NCT07141004 | A Study of Guselkumab Administered Subcutaneously in Treatment of Indian Participants With Psoriatic Arthritis (PsA) | PHASE4 | Recruiting | 100 |
| NCT05256940 | Motivational Interviewing to Address Suicidal Ideation for Veterans at High Risk for Suicide | OTHER | Active Not Recruiting | 368 |
| NCT04165564 | DECAMP 1 PLUS: Prediction of Lung Cancer Using Noninvasive Biomarkers | OTHER | Active Not Recruiting | 85 |
| NCT07553572 | Remote Monitoring and Symptom Management Digital Application | OTHER | Recruiting | 60 |
| NCT04289480 | Safety and Effectiveness of ENTERPRISE 2 Device in the Endovascular Treatment of Intracranial Aneurysms | OTHER | Active Not Recruiting | 164 |
| NCT00552136 | Canadian Orthopaedic Foot and Ankle Society Surgical Treatment of Ankle Arthritis Outcome Study | OTHER | Active Not Recruiting | 250 |
| NCT05957276 | Global Patient Registry of Inherited Retinal Diseases | OTHER | Active Not Recruiting | 888 |
| NCT06085586 | Fibulink Syndesmosis Repair System With Early Full-Weight Bearing | OTHER | Recruiting | 56 |
| NCT07230691 | A Study of Clinical Outcomes in Participants With EGFR Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) in a Real-Wor... | OTHER | Recruiting | 380 |
| NCT06697093 | Polish Nationwide Registry of Diagnostics, Treatment and Outcome in Patients With Cardiogenic Shock | OTHER | Recruiting | 500 |
| NCT02596802 | Fetoscopic Endoluminal Tracheal Occlusion (FETO) for Congenital Diaphragm Hernia | OTHER | Active Not Recruiting | 22 |
| NCT05201781 | A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel | PHASE4 | Recruiting | 295 |
| NCT07213167 | Clinical Evaluation of Low Contrast Visual Performance and Low Light Phenomena in Patients With Various Intraocular Lens... | OTHER | Recruiting | 120 |
| NCT06193863 | An Observational Study to Learn More About How Safe Rivaroxaban is And How Well it Works in Children With Congenital Hea... | OTHER | Active Not Recruiting | 61 |
| NCT06740487 | Advanced Wireless Augmented Reality-Enhanced Exposure Therapy for Posttraumatic Stress Disorder | OTHER | Recruiting | 40 |
| NCT06207071 | Early DHA/ARA Supplementation in Growth-restricted Very Preterm Infants: A Randomized Clinical Trial | OTHER | Recruiting | 152 |
| NCT04023747 | Oxford Pre-cancerous Lymphoproliferative Disorders Study | OTHER | Active Not Recruiting | 574 |
| NCT06643741 | Non-Invasive Preeclampsia Screening and Biobank | OTHER | Recruiting | 6,550 |
| NCT07541261 | A Real-World Study of Guselkumab in Ulcerative Colitis and Crohn's Disease in Saudi Arabia | OTHER | Recruiting | 100 |
| NCT07030517 | A Study to Assess Safety of Teclistamab in Indian Participants With Relapsed and Refractory Multiple Myeloma | PHASE4 | Recruiting | 75 |
| NCT04929210 | A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Diseas... | PHASE4 | Active Not Recruiting | 411 |
| NCT06887920 | Comparison of MiSight 1-Day and Acuvue Oasys for Presbyopia in Myopic Children | OTHER | Active Not Recruiting | 72 |
| NCT07324200 | Objective Assessment of Intraocular Lens Tilt and Decentration | OTHER | Recruiting | 80 |
| NCT07194070 | A Study on Hemolytic Disease of the Fetus and Newborn (HDFN) Through Global Registry | OTHER | Recruiting | 175 |
| NCT07258485 | A Study to Evaluate Sleep Electroencephalogram (EEG) Features (Brain Activity While Sleeping) in Participants With Major... | OTHER | Active Not Recruiting | 94 |
| NCT06614829 | Patient Reported Experiences and Outcomes Associated with Standard C-Section Wound Closure Versus STRATAFIX/DERMABOND PR... | OTHER | Recruiting | 68 |
| NCT06059209 | Enfamil NeuroPro Study | OTHER | Active Not Recruiting | 240 |
| NCT02000284 | Mitochondrial Dysfunction in Autism Spectrum Disorder | OTHER | Active Not Recruiting | 297 |
| NCT06866782 | European Registry of Next Generation Imaging in Advanced Prostate Cancer | OTHER | Recruiting | 600 |
| NCT04108208 | A Study of Apalutamide in Chinese Participants With Non Metastatic Castration Resistant Prostate Cancer (NM-CRPC) | PHASE4 | Active Not Recruiting | 75 |
| NCT01406184 | Durham Connects RCT Evaluation | OTHER | Active Not Recruiting | 2,329 |
| NCT06682949 | Daily Routines, Executive Functioning & ADHD | OTHER | Recruiting | 25 |
| NCT04538664 | A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Particip... | PHASE3 | Active Not Recruiting | 308 |
| NCT05083169 | A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomid... | PHASE3 | Active Not Recruiting | 587 |
| NCT07164443 | A Study of Pasritamig Versus Placebo in Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC) | PHASE3 | Recruiting | 663 |
| NCT05257083 | A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus D... | PHASE3 | Active Not Recruiting | 759 |
| NCT05923073 | A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease | PHASE3 | Recruiting | 120 |
| NCT05552222 | A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Dar... | PHASE3 | Recruiting | 1,590 |
| NCT04794101 | Follow-up Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gen... | PHASE3 | Active Not Recruiting | 97 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.